Virax Biolabs Group Ltd (VRAX) Form 6-K — Aug 26, 2026
Shareholders of Virax Biolabs Group Limited approved an increase in authorized share capital from US$50,000 (2,000,000 ordinary shares) to US$12,500,000 (500,000,000 ordinary shares), creating 498,000,000 new ordinary shares of US$0.025 par value. The ordinary resolution passed narrowly, 61,471 votes for to 54,414 against, at the adjourned Extraordinary General Meeting on August 21, 2026. A second proposal to adopt the fifth amended and restated memorandum and articles of association, tied to the effective date of a planned Share Consolidation, failed to achieve the required two-thirds special resolution approval, drawing 66,754 votes for versus 53,203 against.
Key figures
- Shares Outstanding
- 1344988
- Quorum requirement
- one-third of outstanding shares
- Proposal1 votes for
- 61471
- Proposal2 votes for
- 66754
- Authorized shares after
- 500000000
- Par value per share usd
- 0.025
- Proposal1 votes abstain
- 4342
- Proposal1 votes against
- 54414
- Proposal2 votes abstain
- 270
- Proposal2 votes against
- 53203
- Authorized shares before
- 2000000
- Authorized capital after usd
- 12500000
- Authorized capital before usd
- 50000
- New authorized shares created
- 498000000
- Initial meeting attendance pct
- 6.33
- Adjourned meeting attendance pct
- 8.94
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.